Three new cycloartenol glycosides from the roots of Cimicifuga simplex

Three new cycloartenol triterpene saponins, 3 β,16 α-dihydroxy-12-acetoxy-16,22-cyclo-23-ketone-24 R,25-epoxy-cycloartane-7-ene 3- O- β-D-galactopyranoside ( 1), 24- O-hydroxy-7,8-didehydrohydroshengmanol 3- O- β-D-galactopyranoside ( 2), and 24-epi-24- O-hydroxy-7,8-didehydrohydroshengmanol 3- O- β-D-galactopyranoside ( 3), were isolated from the ethyl acetate soluble fraction of Cimicifuga simplex. Their structures were established by detailed spectroscopic analysis, including extensive 2D-NMR data. This is the first time that a 16,22-cyclo type glycosidesaponin from aCimicifuga species was reported. The immunosuppressive activities of the new compounds were evaluated by a ConA-stimulated T splenocyte proliferation assay in vitro.     

硼替佐米联合化疗治疗复发难治外周T细胞淋巴瘤3例

外周T细胞淋巴瘤(PTCL)是一类具有高度异质性的恶性淋巴肿瘤,临床治疗棘手,目前最新NCCN指南中,PTCL无论一线和二线治疗都推荐临床试验,说明目前还没有统一的比较理想的治疗方案〔1〕。硼替佐米(万珂)目前已广泛用于治疗多     

右美托咪定用于老年高血压患者椎管内麻醉的临床研究

目的探讨右美托咪定用于老年高血压患者椎管内麻醉的临床效果及其安全性。方法选择行下肢骨折内固定术老年高血压患者68例,按随机数字表法分为试验组(38例)和对照组(30例),患者行腰硬联合麻醉后,试验组静脉泵注右美托咪定至手术结束,对照组以生理盐水静脉泵注至手术结束。比较两组患者术中生命体征、Ramsay镇静评分、麻醉效果、硬膜外总用药量及不良反应发生情况。结果试验组较对照组术中血流动力学变化更稳定,Ramsay镇静评分高,麻醉效果优,硬膜外总用药量更少,且不良反应的发生率更低,差异均有统计学意义(P<0.05)。结论右美托咪定减少老年高血压患者硬膜外总用药量,麻醉效果良好,且无明显不良反应,用于老年高血压患者椎管内麻醉是安全、有效的。     

Efficacy of cytokine removal by plasmadiafiltration using a selective plasma separator: in vitro sepsis model

More effective removal of pro- and anti-inflammatory cytokines may play an important role in the treatment of sepsis. Plasmadiafiltration (PDF) with a larger selective plasma separator was performed to study the cytokine and plasma protein permeability profiles of the membrane in an in vitro sepsis model. The in vitro sepsis model was constructed by exposure of human whole blood to bacterial lipopolysaccharide. EVACURE 2A, a selective plasma separator, was placed in the blood circuit of PDF. Sieving coefficients of cytokines and plasma protein were tested in post-dilution PDF mode at the following operating parameters: blood flow rate 150 mL/min; dialysate flow rate 33.33 mL/min; replacing fluid flow rate 6.67 mL/min; ultrafiltration rate 5 mL/min. An enzyme linked immunoadsorbent assay was used to measure the concentrations of tumor necrosis factor-α (TNF-α), high-mobility group box 1 protein (HMGB1), interleukin-1β (IL-1β), interleukin-1 receptor antagonist (IL-1ra), interleukin-2 (IL-2), interleukin-2 receptor (IL-2r), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10) in plasma and ultrafiltrate. Sieving coefficients of different solutes ranged from 0.1 to 1.0 at first, decreased 10%-60% after 1 h of PDF, and then remained stable. Total clearance rates of cytokines ranged from 15 to 80 mL/min. The concentrations of cytokines decreased 20-80% after 1 hour of PDF. The sieving coefficient of albumin was 0.1 at first and then decreased to 0.05 after 1 hour of therapy. Plasmadiafiltration with Evacure 2A plasma separator can effectively remove almost all of the inflammatory mediators with low albumin loss.     

Allitridi inhibits transient outward potassium currents in human atrial myocytes

1. It has been reported that allitridi, an active compound extracted from garlic, has many cardiovascular effects. However, it remains unknown whether allitridi affects major repolarization currents, such as the transient outward K(+) current (I(to) ), ultrarapid delayed rectifier K(+) current (I(Kur)) and the L-type Ca(2+) current (I(Ca)), in human atrial myocytes. 2. In the present study, we investigated the effects of allitridi on I(to), I(Kur), I(Ca) and the action potential in human isolated atrial myocytes using the whole-cell patch recording technique. 3. Allitridi reversibly inhibited I(to), but not I(Kur) and I(Ca), in human atrial myocytes. These effects of allitridi on I(to) were concentration dependent (IC(50) = 44.9 μmol/L). Inactivation of I(to) was accelerated and the voltage-dependent inactivation potential was shifted towards the negative direction. Allitridi (30 μmol/L) significantly prolonged action potential duration in human atrial myocytes. 4. The results of the present study indicate that allitridi inhibits I(to), but not I(Kur) and I(Ca), and prolongs the action potential duration in human atrial myocytes.     

抑制CC类趋化因子配体5基因表达对乳腺癌细胞增殖能力的影响

目的 探讨抑制CC类趋化因子配体5(CCL5)基因表达对人乳腺癌细胞增殖能力的影响.方法 用特异性CCL5 RNA干扰(RNAi)序列慢病毒载体感染人乳腺癌细胞MCF-7和MDA-MB-231,分别为KD1组和KD2组;另在MCF-7和MDA-MB-231细胞中分设阴性病毒载体感染的阴性对照组(NC1组和NC2组)和未感染组(CON1组和CON2组).采用实时定量逆转录聚合酶链反应(RT-PCR)检测转染病毒后乳腺癌细胞中CCL5的表达,四甲基偶氮唑蓝(MTT)比色法和流式细胞术(FACS)分析细胞的增殖情况,平板克隆形成实验观察细胞的克隆形成能力.结果 CCL5 RNAi慢病毒可显著降低MCF-7和MDA-MB-231细胞中CCL5基因的表达.MTF法检测结果显示,在不同的培养时间,MCF-7和MDA-MB-231细胞的KD组、NC组与CON组细胞培养上清A值差异均无统计学意义(均P＞0.05).FACS分析结果显示,KD1组、NC1组和CON1组的增殖指数(PI)值分别为0.48±0.03、0.43±0.01和0.45±0.02;KD2组、NC2组和CON2组的PI值分别为0.48±0.02、0.44±0.05和0.47±0.02(两两比较,均P＞0.05).荧光显微镜下观察显示,KD组的克隆体积及每克隆的细胞数明显小于NC组和CON组.KD1组和KD2组克降数目(0.34±0.08和0.33±0.10)明显少于NC1组(0.81±0.12)、NC2组(0.97±0.09)、CON1组(0.92±0.12)和CON2组(1.04±0.07),差异有统计学意义(P＜0.05).结论 CCL5基因的表达下调对乳腺癌MCF-7和MDA-MB-231细胞群体倍增时间无明显影响,但可显著降低细胞的克隆形成能力,从而使肿瘤细胞的恶性增殖受到抑制.

Abstract：

Objective To investigate the effect of suppression of CCI5 ligand gene on the proliferation of human breast cancer cells. Methods A lentiviral vector carrying a short interfering RNA (siRNA) targeting CCL5 was transfected into human breast cancer cell line MCF-7 and MDA-MB-231 cells.The expression of CCL5 mRNA in the cells was detected by real-time PCR. The proliferation of MCF-7 and MDA-MB-231 cells was assessed by MTT assay and FACS assay, and the colony formation ability of both cell lines were measured, respectively. Results Real time PCR showed a good knockdown effect of CCL5 in both cell-lines. Colony-forming assay showed that the ability of colony formation of MCF-7/CCL5-siRNA and MDA-MB-231/CCL5-siRNA was decreased markedly. The colony number of MCF-7/CCL5-siRNA group was (0. 34 ± 0. 08), significantly lower than 0. 81 ± 0. 12 in the MCF-7/CCL5-N group and 0.92 ± 0.12 in the MCF-7 group (P ＜ 0. 05). The colony number of MDA-MB-231/CCL5-siRNA group was 0. 33 ± 0. 10,significantly lower than 0.97 ±0.09 in the MDA-MB-231/CCL5-N group and 1.04 ±0.07 in the MDA-MB-231 group (P ＜0.05). However, MTT assay revealed that the proliferation of MCF-7/CCL5-siRNA cells was not significantly different from that of MCF-7/CCL5-N or MCF-7 cells, respectively (P ＞0.05), and the same result was found in MDA-MB-231 cells. FACS assay showed that the proliferation index (PI) of groups MCF-7/CCL5-siRNA, MCF-7/CCL5-N and MCF-7 were 0.48 ± 0. 03, 0. 43 ± 0. 01 and 0.45 ±0. 02. The PI of groups MDA-MB-231/CCL5-siRNA, MDA-MB-231/CCL5-N and MDA-MB-231 cells were 0. 48 ± 0.02, 0.44 ± 0.05 and 0. 47 ± 0. 02. There was no statistical difference among them ( P ＞ 0.05 ).Conclusion The down-regulation of CCL5 gene in human breast cancer cells may significantly suppress their colony formation ability, rather than affecting their population doubling time to some extent.     

复方莪倍软膏治疗斑块状银屑病的临床观察

目的观察复方莪倍软膏对于斑块状银屑病的治疗作用及安全性。方法采用区组随机、开放、阳性西药及安慰剂平行对照的方法。将120例入选患者在口服扫癣丸情况下,分别采用复方莪倍软膏、达力士软膏、软膏基质外涂治疗4周,疗程结束后评价红斑、浸润、鳞屑、瘙痒的改善情况及皮损面积改变情况及安全性。并观察症状改善时间。结果局部症状改善情况：中药组和西药组红斑、鳞屑、浸润、瘙痒程度治疗前后评分比较,差异有显著性（P〈0．01）,而安慰剂组仅鳞屑评分差异有显著性（P〈0．01）;治疗后两治疗组与安慰刺组比较,差异均有显著性（P〈0．01）。中药组瘙痒症状改善时间少于西药组及安慰剂组,差异有显著性（P〈0．01）,而其他症状改善时间差异无显著性;中药组及西药组的红斑、鳞屑、浸润症状改善时间均少于安慰荆组,差异有显著性（P=0．01）;中药组与西药组不良事件发生比较差异无显著性;而中药组复发相对少于西药组。结论复方莪倍软膏能够有效改善斑块状银屑病的皮损症状,其疗效不低于阳性西药。     

异黄酮并木脂素类化合物的结构类型与生物活性

异黄酮并木脂素类化合物是近20年来发现的异黄酮与木脂素发生骈和而形成的一类化合物,就目前发现的异黄酮并木脂素类化合物,其结构类型仅有2种,在植物界的分布也是仅存在豆科植物中,因此,其生物活性也相对报道的较少。就此类化合物的结构类型、生物活性及其结构研究法的研究进展进行了综述。